Ajay Chari, MD

Articles

Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

November 1st 2024

Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.

Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

November 1st 2024

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.

Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

October 25th 2024

Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.

MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

October 25th 2024

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

October 18th 2024

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

October 18th 2024

Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.

Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

October 4th 2024

Ajai Chari, MD, discusses the potential role for CAR T-cell therapies in the early-relapsed setting for patients with multiple myeloma.

Dr Chari on Current Unmet Needs to Address in Multiple Myeloma Treatment

March 7th 2024

Ajai Chari, MD, discusses unmet needs in multiple myeloma, as well as what oncologists should know about the current treatment paradigm for this disease.

Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting

March 7th 2024

Ajai Chari, MD, discusses the 2024 OncLive® Bridging the Gaps in Hematologic Malignancies meeting, highlighting the treatment of multiple myeloma.

Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

December 15th 2023

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

September 25th 2023

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

September 20th 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma

September 18th 2023

Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

September 14th 2023

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

Dr. Chari on Avenues for Future Research in Newly Diagnosed Multiple Myeloma

January 20th 2023

Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

December 22nd 2022

Dr Ajay Chari reviews the results from the MonumenTAL-1 trial which evaluates the use of talquetamab, a GPRC5D x CD3 bispecific antibody in patients with relapsed refractory multiple myeloma.